Autio KA, Higano CS, Nordquist L, Appleman LJ, Zhang T, Zhu X-H, Babiker H, Vogelzang NJ, Prasad SM, Schweizer MT, et al. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2023;11(3).